2026 ATI RN PHARMACOLOGY
2023 EXAM WITH NGN
QUESTIONS AND ANSWERS
LATEST MOCK PRACTICE SET
168 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
2026 ATI RN PHARMACOLOGY 2023 EXAM WITH NGN QUESTIONS AND ANSWERS. It contains 168
carefully selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 168 Questions
Foundations - Application - 2026 ATI RN Pharmacology 2023 WITH NGN AND Pharmacology FOR
Registered Nurses Undergraduate YEAR 3 / Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
2026 ATI RN Pharmacology 1-28 Receiving, Mechanism, Requires, Effect, Develops
2023 WITH NGN AND
Pharmacology FOR
Registered Nurses
Undergraduate YEAR 3 /
Graduate
Receiving 29-56 Appropriate, Prescribed, Therapy, Infusion, Therapeutic
Prescribed 57-84 Develops, Appropriate, Infusion, Kidney, Phenytoin
Appropriate 85-112 Prescribed, Explains, Develops, Started, Chronic
Therapy 113-140 Digoxin, Prescribed, Develops, Effect, Receiving
Explains 141-168 Develops, Phenytoin, Appropriate, Receiving, Started
TOTAL 168 All questions include answers and detailed rationales
,Section A - 2026 ATI RN Pharmacology 2023 WITH NGN
AND Pharmacology FOR Registered Nurses Undergraduate
YEAR 3 / Graduate
Q1.
A patient with a history of chronic alcoholism and cirrhosis presents with acute
acetaminophen toxicity. Which factor most significantly alters the hepatotoxic threshold
and requires dose adjustment?
A. Enhanced glucuronidation due to enzyme B. Depleted glutathione stores and induced
induction CYP2E1 activity
C. Reduced renal clearance of the toxic D. Increased protein binding of
metabolite acetaminophen
Correct: B - Depleted glutathione stores and induced CYP2E1 activity
Rationale:Chronic alcohol use induces CYP2E1, leading to increased production of the toxic
metabolite NAPQI, and also depletes glutathione, reducing detoxification capacity. This
lowers the threshold for hepatotoxicity. Glucuronidation is not enhanced; it may be impaired.
Renal clearance is not the primary determinant of hepatotoxicity, and protein binding changes
are not significant.
Q2.
A patient on long-term warfarin therapy requires an antibiotic for a urinary tract infection.
Which antimicrobial is most likely to cause a clinically significant elevation in INR due to
CYP2C9 inhibition?
A. Ciprofloxacin B. Azithromycin
C. Nitrofurantoin D. Cephalexin
Correct: A - Ciprofloxacin
Rationale:Ciprofloxacin inhibits CYP2C9, the enzyme that metabolizes the S-enantiomer of
warfarin, leading to increased warfarin levels and INR. Azithromycin has minimal CYP
interactions, nitrofurantoin does not inhibit CYP2C9, and cephalexin has no significant effect
on warfarin metabolism.
Q3.
A patient is prescribed a drug that is a P-glycoprotein (P-gp) substrate. Which concurrent
medication is most likely to increase the oral bioavailability of this drug by inhibiting P-gp
in the gut?
A. Rifampin B. Verapamil
Page 3
, Section A - 2026 ATI RN Pharmacology 2023 WITH NGN AND Pharmacology FOR Registered Nurses Undergraduate YEAR 3 / Graduate
C. Phenytoin D. St. John's Wort
Correct: B - Verapamil
Rationale:Verapamil is a P-gp inhibitor, blocking efflux of the substrate from enterocytes,
thereby increasing absorption and bioavailability. Rifampin, phenytoin, and St. John's Wort
are P-gp inducers, which decrease bioavailability by enhancing efflux.
Q4.
A patient with heart failure is started on digoxin. Which serum electrolyte abnormality
increases the risk of digoxin toxicity by enhancing the drug's binding to Na+/K+-ATPase?
A. Hyperkalemia B. Hypokalemia
C. Hypercalcemia D. Hypomagnesemia
Correct: C - Hypercalcemia
Rationale:Hypercalcemia increases the inotropic effect of digoxin and predisposes to toxicity,
as calcium competes with digoxin at the Na+/K+-ATPase pump, enhancing its binding.
Hypokalemia also increases toxicity, but by reducing pump activity, not by enhancing binding.
Hyperkalemia is protective, and hypomagnesemia potentiates toxicity but does not enhance
binding.
Q5.
A patient is receiving an intravenous infusion of norepinephrine. Which concurrent
medication is most likely to result in severe hypertensive crisis due to a
pharmacodynamic interaction?
A. A beta-blocker B. An MAO inhibitor
C. A loop diuretic D. An ACE inhibitor
Correct: B - An MAO inhibitor
Rationale:MAO inhibitors prevent the breakdown of norepinephrine, leading to accumulation
at the synapse and exaggerated sympathetic response, causing hypertensive crisis.
Beta-blockers may blunt the response, while diuretics and ACE inhibitors do not potentiate
norepinephrine's pressor effect.
Q6.
Which of the following drug-drug interactions is correctly paired with its mechanism?
A. Clarithromycin + simvastatin: increased B. Fluconazole + warfarin: decreased
statin metabolism via CYP3A4 induction warfarin effect via CYP2C9 inhibition
Page 4
2023 EXAM WITH NGN
QUESTIONS AND ANSWERS
LATEST MOCK PRACTICE SET
168 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
2026 ATI RN PHARMACOLOGY 2023 EXAM WITH NGN QUESTIONS AND ANSWERS. It contains 168
carefully selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 168 Questions
Foundations - Application - 2026 ATI RN Pharmacology 2023 WITH NGN AND Pharmacology FOR
Registered Nurses Undergraduate YEAR 3 / Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
2026 ATI RN Pharmacology 1-28 Receiving, Mechanism, Requires, Effect, Develops
2023 WITH NGN AND
Pharmacology FOR
Registered Nurses
Undergraduate YEAR 3 /
Graduate
Receiving 29-56 Appropriate, Prescribed, Therapy, Infusion, Therapeutic
Prescribed 57-84 Develops, Appropriate, Infusion, Kidney, Phenytoin
Appropriate 85-112 Prescribed, Explains, Develops, Started, Chronic
Therapy 113-140 Digoxin, Prescribed, Develops, Effect, Receiving
Explains 141-168 Develops, Phenytoin, Appropriate, Receiving, Started
TOTAL 168 All questions include answers and detailed rationales
,Section A - 2026 ATI RN Pharmacology 2023 WITH NGN
AND Pharmacology FOR Registered Nurses Undergraduate
YEAR 3 / Graduate
Q1.
A patient with a history of chronic alcoholism and cirrhosis presents with acute
acetaminophen toxicity. Which factor most significantly alters the hepatotoxic threshold
and requires dose adjustment?
A. Enhanced glucuronidation due to enzyme B. Depleted glutathione stores and induced
induction CYP2E1 activity
C. Reduced renal clearance of the toxic D. Increased protein binding of
metabolite acetaminophen
Correct: B - Depleted glutathione stores and induced CYP2E1 activity
Rationale:Chronic alcohol use induces CYP2E1, leading to increased production of the toxic
metabolite NAPQI, and also depletes glutathione, reducing detoxification capacity. This
lowers the threshold for hepatotoxicity. Glucuronidation is not enhanced; it may be impaired.
Renal clearance is not the primary determinant of hepatotoxicity, and protein binding changes
are not significant.
Q2.
A patient on long-term warfarin therapy requires an antibiotic for a urinary tract infection.
Which antimicrobial is most likely to cause a clinically significant elevation in INR due to
CYP2C9 inhibition?
A. Ciprofloxacin B. Azithromycin
C. Nitrofurantoin D. Cephalexin
Correct: A - Ciprofloxacin
Rationale:Ciprofloxacin inhibits CYP2C9, the enzyme that metabolizes the S-enantiomer of
warfarin, leading to increased warfarin levels and INR. Azithromycin has minimal CYP
interactions, nitrofurantoin does not inhibit CYP2C9, and cephalexin has no significant effect
on warfarin metabolism.
Q3.
A patient is prescribed a drug that is a P-glycoprotein (P-gp) substrate. Which concurrent
medication is most likely to increase the oral bioavailability of this drug by inhibiting P-gp
in the gut?
A. Rifampin B. Verapamil
Page 3
, Section A - 2026 ATI RN Pharmacology 2023 WITH NGN AND Pharmacology FOR Registered Nurses Undergraduate YEAR 3 / Graduate
C. Phenytoin D. St. John's Wort
Correct: B - Verapamil
Rationale:Verapamil is a P-gp inhibitor, blocking efflux of the substrate from enterocytes,
thereby increasing absorption and bioavailability. Rifampin, phenytoin, and St. John's Wort
are P-gp inducers, which decrease bioavailability by enhancing efflux.
Q4.
A patient with heart failure is started on digoxin. Which serum electrolyte abnormality
increases the risk of digoxin toxicity by enhancing the drug's binding to Na+/K+-ATPase?
A. Hyperkalemia B. Hypokalemia
C. Hypercalcemia D. Hypomagnesemia
Correct: C - Hypercalcemia
Rationale:Hypercalcemia increases the inotropic effect of digoxin and predisposes to toxicity,
as calcium competes with digoxin at the Na+/K+-ATPase pump, enhancing its binding.
Hypokalemia also increases toxicity, but by reducing pump activity, not by enhancing binding.
Hyperkalemia is protective, and hypomagnesemia potentiates toxicity but does not enhance
binding.
Q5.
A patient is receiving an intravenous infusion of norepinephrine. Which concurrent
medication is most likely to result in severe hypertensive crisis due to a
pharmacodynamic interaction?
A. A beta-blocker B. An MAO inhibitor
C. A loop diuretic D. An ACE inhibitor
Correct: B - An MAO inhibitor
Rationale:MAO inhibitors prevent the breakdown of norepinephrine, leading to accumulation
at the synapse and exaggerated sympathetic response, causing hypertensive crisis.
Beta-blockers may blunt the response, while diuretics and ACE inhibitors do not potentiate
norepinephrine's pressor effect.
Q6.
Which of the following drug-drug interactions is correctly paired with its mechanism?
A. Clarithromycin + simvastatin: increased B. Fluconazole + warfarin: decreased
statin metabolism via CYP3A4 induction warfarin effect via CYP2C9 inhibition
Page 4
